Abstract: This invention provides a composition comprising notochord and extracts thereof in therapeutic amounts. The invention more specifically relates to a method of treating arthritis in mammals, more particularly rheumatoid arthritis in humans through the enteral administration of notochord, notochord extracts or mixtures thereof. In a preferred embodiment, collagen obtained from sturgeon is enterally administered to a human at from 1.0 .mu.g to 1.05 gms per day.

Abstract: The present invention relates generally to a method of producing plant proteins for use in nutritional products that have reduced levels of phytoestrogens, manganese or nucleotides. More specifically, this invention is directed to a method of using ion exchange technology to remove phytoestrogens, manganese or nucleotides from plant proteins. This invention is also directed to the plant protein product resulting from the inventive process and to nutritional products that use the plant protein product as a source of amino nitrogen.

Abstract: Prolamine fractions of grain proteins, applied as a single coating in weight ratios of 5 to 100% relative to the active substance being coated, result in the production of a liquid suspension which effectively masks the taste of orally administered drugs which often are extremely bitter. The taste masking is stable over prolonged periods of storage time of the suspension. The prolamine coating does not restrict the immediate bioavailability of the active substance. Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fiber, analgesics, enzymes and hormones. Zein, gliadin or a mixture thereof, particularly in combination with between 2.

Abstract: A powdered beverage concentrate contains a source of calcium, vitamin D, a stabilizing gum such as gum arabic, and vegetable oil. A beverage can be made by reconstituting the beverage concentrate with water, fruit juice, or any other suitable liquid matrix.

Abstract: Prolamine fractions of grain proteins, applied as a single coating in weight ratios of 5 to 100% relative to the active substance being coated, result in the production of a liquid suspension which effectively masks the taste of orally administered drugs which often are extremely bitter. The taste masking is stable over prolonged periods of storage time of the suspension. The prolamine coating does not restrict the immediate bioavailability of the active substance. Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fiber, analgesics, enzymes and hormones. Zein, gliadin or a mixture thereof, particularly in combination with between 2.

Abstract: A liquid beverage concentrate and a beverage containing the concentrate are aqueous matrices fortified with calcium and vitamin D. The water soluble vitamin D is kept in suspension by a gum and a vegetable oil. The beverage may be carbonated or non-carbonated.

Abstract: Fish oil is stored refrigerated under a nitrogen blanket until it is added to an enteral nutritional product during product manufacture. While the nutritional product is passing through a conduit the fish oil is added to the product at a uniform ratio such that the fish oil is evenly disbursed throughout the product, and thereafter the product is homogenized and heat treated.

Abstract: A method for dye marking a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient includes the steps of: (1) providing apparatus such as a formulation chamber, e.g., a drip chamber, connectable to the supply container, with at least one sustained release reservoir containing a physiologically acceptable and dispersible marker dye positioned within the formulation chamber, and, liquid communication means connecting the formulation chamber to the feeding tube of a patient; (2) providing a supply container containing the nutritional product; (3) connecting the formulation chamber to the supply container and the liquid commmunication means to the feeding tube; and (4) flowing the dye-marked nutritional product through the apparatus and into the feeding tube.

Abstract: An enteral nutritional product has been formulated for persons who are currently undergoing radiation therapy and/or chemotherapy. The nutritional product has a protein system which includes a soy protein hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 fatty acids that is in the range of about 1.3:1 to 2.5:1.

Abstract: An apparatus and method are disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply to a feeding tube delivering the modified liquid enteral nutritional product to the gastrointestinal tract of a patient. At least one beneficial agent not in controlled release dosage form in a useful, dose unit, amount, is disposed within a formulation chamber so as to be taken up in a liquid enteral nutritional product traversing the formulation chamber while feeding the modified nutritional product into the gastrointestinal tract of a patient. The beneficial additive(s) are selected from nutrients, medicaments, probiotics, or diagnostic agents, or mixtures thereof, each in a dosage form that is dispersible in the medium of the liquid enteral nutritional product in less than two hours.

Abstract: An apparatus is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply thereof, such as a hangable container, to a feeding tube delivering the liquid enteral nutritional product to the gastrointestinal tract of a patient. The apparatus has at least one formulation chamber, such as a drip chamber, with at least one controlled release dosage form unit in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving type material, or a quantity of fine hollow permeable fibers located therein. The controlled release dosage form unit or units contain at least one beneficial agent selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, to any of which a physiologically acceptable marker dye in controlled release dosage form and/or the same or different beneficial agent not in controlled release dosage form may be added.

Abstract: A method is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. During enteral tube feeding the nutritional product passes through a formulation chamber, e.g., a drip chamber, having located therein at least one controlled release dosage form unit containing at least one beneficial agent. The beneficial agent may be selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, and any such together with a physiologically acceptable marker dye in controlled release dosage form and/or the same or different additional beneficial agent not in controlled release dosage form. Controlled release dosage forms may be of a conventional sustained release type or an osmotically driven delivery device.

Abstract: An apparatus is useful for dye marking a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. A formulation chamber, such as a drip chamber, is connectable to the supply container. At least one sustained release reservoir containing a physiologically acceptable marker dye is positioned within the formulation chamber, or if not, is included as part of a kit. The sustained release reservoir may be in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving material, or chopped hollow fibers having permeable walls. A liquid communication means connects the formulation chamber to the feeding tube of a patient. The marker dye may be a colorant dye or a fluorescing dye or a mixture thereof.

Abstract: A liquid enteral nutritional product contains a protein system of, by weight, about 50-90% of a soy protein hydrolysate having a degree of hydrolysis in the range of 14 to 17% and not more than 50% of one or more intact protein sources. The nutritional product may also contain an emulsifier, Iota carrageenan and Kappa carrageenan.

Abstract: A method of providing enteral nutritional support to a person who is currently undergoing chemotherapy and/or radiation therapy involves including in the person's diet an enteral nutritional product having a protein system which includes a soy protein hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 fatty acids that is in the range of about 1.3:1 to 2.5:1.

Abstract: Enteral nutritional support for a person infected with human immunodeficiency virus is provided by including in the diet a nutritional product which contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

Abstract: An enteral nutritional product for persons infected with human immunodeficiency virus contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

Abstract: A process for aseptically processing a milk based infant formula includes the steps of adding citrate ions to the formula at a concentration of at least 128 ppm and adjusting the pH to be at least 6.8 before subjecting the formula to a temperature of at least 132.degree. C.

Abstract: A novel process for the removal of phosphorous from mammalian milk, preferably bovine skim milk, has been developed. The process involves passage of the milk at an elevated temperature through a Type I or Type II macroporous or gel type strong base ion exchange material in the chloride or carbonate form. The weak base anion sites inherent to the ion exchange material have been neutralized. The ion exchange material can easily be regenerated.

Abstract: An apparatus has the capacity to satisfactorily blend a liquid with a powder and pump the resultant viscous slurry in a single stage operation. The apparatus has a vertically oriented drive shaft with a bladed impeller attached to the drive shaft. A housing surrounds a mixing chamber in which the impeller is located. The lower end of a powder inlet tube is disposed in very close proximity to the highest vertical extent of the impeller blades. A liquid enters the mixing chamber exterior of the powder inlet tube. The resultant slurry leaves the mixing chamber via a slurry discharge port.